Хадасса, Кирьят Хадасса, Иерусалим, 91120, Израиль

info@hadassah-med.ru Израиль:
+972-732-700-202
Отделения
Поиск

Профессор Хуберт

Профессор Хуберт

Имя: Аяла Хуберт

Специализируется: гастроэнтерология, онкология.

Должность: Руководитель центра диагностики и лечения опухолей ЖКТ

Обучалась:

  • получила диплом врача в Иерусалимском университете (Израиль);
  • Стала участником программы по изучению онкологических заболеваний в Милане (Италия);
  • Прошла годичное обучение на базе Стэндфордского университета (США);
  • Проходила стажировку в Техасском центре медицины (США).
  • лектор Еврейского университета в Иерусалиме.
  • старший преподаватель Еврейского университета в Иерусалиме.

Занятость в Еврейском университете:

  • 1997 Инструктор, Медицинская онкология / радиационная онкология, Еврейский университет, Иерусалим.
  • 1/4/2001 лектор Еврейского университета в Иерусалиме.
  • 10/2012 старший преподаватель Еврейского университета в Иерусалиме.

Проводит:

  • лечение опухолей желудка, кишечника, других органов ЖКТ;
  • развивает возможности радиотерапии.

Дополнительные обязанности

  • С 1998 года по сегодняшний день: старший врач онкологического отделения университетской клиники “Хадасса”.
  • 2005-2013: член Комитета докторских диссертаций, Еврейский университет, Школа медицины.
  • 2009-настоящее время: руководитель центра рака желудочно-кишечного тракта в клинике “Хадасса”.
  • 2013-2015: Член преподавательско-студенческого комитета, Еврейский университет, Школа медицины.

Преподавательская деятельность: преподавала онкологию на медицинском факультете Иерусалимского университета.

Общие сведения: является известным специалистом в области лечения онкологических заболеваний желудочно-кишечного тракта. Доктор Хуберт развивает лечебное направление радиотерапии. Член многих национальных и международных врачебных организаций. Имеет двоих детей.

Активности в других научных и исследовательских учреждениях

  1. 9/96 “Медицинская онкология”. ESO, Милан, Италия. (5 дней)
  2. 10/1997 “Медицинская онкология и лучевая терапия”. UCSF и Стэнфордский университет, США. (1 месяц)
  3. 7/2003 Посещение GI Oncology Program. Доктор медицины Андерсон, Техасский медицинский центр, Хьюстон, штат Техас.
  4. 10/2007 Посещение GI Oncology Program. Больница Paul Brousse, Париж, Франция.

Другая активность

  • 2007- настоящее время Министерство здравоохранения, суб-комитет Национального медицинского страхования.
  • 2010 член комитета, GIDEON Publications European study
  • 9/2011: Организатор: 1-й израильский конференция по онкологии в Сообществе. Inbal Hotel, Иерусалим
  • 12/2010 редактор, Oncology Present & Future Journal, медицинские Публикации, СМИ, Израиль.
  • 2011 Учебный инструктор, Интернет школа рака толстой кишки, одобрена Израильской Медицинской Ассоциации CME.
  • 5/2011: Организатор: Израильская конференция по онкологии: Новое о раке прямой кишки и GIST. Тель-Авив Порт.
  • 9/2011: Организатор: 1-й израильской конференции онкологии в сообществе
  • 10/2012: Организатор: Конференция о новых данных о колоректальном раке для онкологов. “Хадасса”, Иерусалим.
  • 11/2012: Организатор: 2-й израильской конференции по онкологии в сообществе. Леонардо Сити Тауэр, Рамат-Ган.
  • 12/2012: Организатор: Клиническая конференция, многопрофильный подход к колоректальному раку. Хадасса.
  • 2/2014 Председатель израильской группы онкологии желудочно-кишечного тракта (IGOG).
  • 3/2015 Ревизор, этап II: клиническая онкологии, Еврейский университет в Иерусалиме, медицинская школа.
  • 11/2015 Организатор и Председатель: Первая конференция Израиля о злокачественных новообразованиях желудочно-кишечного тракта, Общество Клинической Онкологии Израиля, Кейсарии, Израиль.

Исследовательские гранты

  • 1995 The Landau Family Prize for Oncology Research
  • 9 / 01-: Hadassah Womens Health Research, “In research for a characteristic immunophenotype for BRCA1 and BRCA2 related breast cancer” Dr. Ayala Hubert, Dr. Eli Pikarsky, Prof. Tamar Peretz.
  • 3/06-12/06 : Israel Cancer Association, “The contribution of patterns of maternal bonding between mothers with breast cancer and their adolescent daughter abilities to self identify.” Dr. Ayala Hubert, Dr. Inbar Cohen.
  • 2008, Zalsberg foundation, ” The role of galectin-1 as a potential key regulator linking inflammation to development of hepatocellular carcinoma”. Tamara Potikha, Ayala Hubert, Orit Pappo, Devorah Olam, Daniel Goldenberg
  • 2012  Munsa Grant. “Genomic features in colon cancer among BRCA1 and 2 carriers”.  Dr. Ayala Hubert, Dr. Aviad Zick, Prof. Eli Pikarsky, Dr. Luna Kadouri

Преподавание в Еврейском университете

Студентам магистратуры:

  • 2007-2008 Dalit Verner. “The approach to pain control in Oncology nurses vs. non Oncology nurses.” School of Public Health
  • 2009- настоящее время Elisheva Jan. “Breast cancer: the relationship between degree of theological belief and the decision making process. School of Nursing

Студентам-докторантам:

  • 1999-2000 Ofra Meirovich. ” The influence of the I1307K mutation in the APC gene on the clinical presentation of breast and ovarian cancer in carriers of BRCA mutations.”
  • 2004-2007 Keren Or-Raviv. “Multi Markers RT-PCR Assay for the Detection of minimal residual disease in  Pleural Effusion of Breast Cancer Patients”.
  • 2009-2010 Smadar Schiffer. ” Characterization of Subgroups in Patients Suspected to be Carriers of the Lynch Syndrome (HNPCC), Within the Israeli Population of Colorectal Cancer Patients”.

Исследования с кандидатами наук:

  • 2000-2002 Dr. Igor Nemirovsky. “The Prevalence of the Mutation BRCA2 8765 DEL AG in Yemenite Jews.”

Список публикаций

Докторская диссертация

Название: Effect of Theophylline on Erythocytosis in Chronic Obstructive Pulmonary Disease

Руководитель: Dr. Rani Oren M.D.

Публикация: Oren R. Beeri M. Hubert A. Kramer M. Matzner Y. “Effect of Theophylline on Erythocytosis in Chronic Obstructive Pulmonary Disease. Archives of Int. Med. 157(13): 1474-8;Jul.1997. 7.508;6/103;9. #19

Книги

Hubert A. “GI Cancer” chapter in Medicine Oncology. Forum Media, Israel (Hebrew). 2009

Главы в коллекциях

  1. Hubert A. “Treatment of antibodies in Gastrointestinal Cancer” BAMA, Isr.Canc.Soc. 15:11-14, March 2005.

    2.Hubert A. “The therapeutic approach in treating gastric, esophageal and pancreatic cancer” in Innovations and updates in Gastric cancer. Figer A. (Ed.), Aurora Group Press. P11-13, 2001 (Hebrew)

  1. Hubert A. “Adenocarcinoma of the stomach: A combined treatment”, Medicine Cancer P42-44, Sep-Nov 2006.
  2. Hubert A “The systemic treatment of metastatic pancreatic cancer”. GI Malignancies can be treated and prevented. AURORA Group Press. 7/2009.
  3. Hubert A, Goldberg Y. “Counseling and diagnosis of HNPCC”. Oncology present and future. Medical Media Group. 3/2010.
  4. Hubert A. “The systemic treatment in metastatic pancreatic cancer”. Oncology present and future. Medical Media Group. 9/2011.
  5. Hubert A. “Updates in metastatic colorectal cancer treatment.” Oncology present and future. Medical Media Group. 12/2012.

Статьи:

Оригинальные работы в обзорах журналов:

  1. Barak V PI. Nisman B PI. Roisman I. C Hubert A. C Burde B. C Peretz T PI. (1994) “TPS in evaluation of response to Taxol in Interferon therapy in breast cancer patients.” Tumor Marker Oncology. 9(2):89. X; X; 5:4.
  2. Oren R. PI Beeri M. PI Hubert A. S Kramer M. C Matzner Y. PI (1997) “Effect of Theophylline on Erythocytosis in Chronic Obstructive Pulmonary Disease. Archives of Int. Med. 157(13): 1474-8; 11.462; 7/153; 11:11.
  3. Oren R, PI Maaravi Y C, Karmeli F C, Kenet G C, Zeidel L, C Hubert A, C Eliakim R. PI (1997) “Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis.” Aliment Pharmacol. Ther. 11(2):341-5. 3.769; 17/74; 49/261; 7:7.
  4. Peretz T, PI Kaplan Denour A, C Baider L, C Hubert A, C Stephanos S, C Barak V. PI (1997) “The combination of Interferon and Tamoxifen for patients with advanced breast cancer and negative estrogen receptors.” The Breast. 6(4):190-193. 2.491; 16/79; 101/194; 6:5.
  5. Oren R PI, Zajicek G, C Maaravi Y , C Kenet G, C Karmely F, C Hubert A, C Raanani P, C Arber N. PI (1997) “Methimazole slows hepatocyte streaming in rats.” Dig Dis Sci. 42(7):1433-7. 2.117; 42/74; 8:8.
  6. Barak V, PI Nisman B, PI Roisman I, C Hubert A, C Farbstein H, C Baider L, C Kaplan A, C Halperin T, C Stephanos S, C Peretz T. PI (1997) “TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons” of Tumor Marker Oncology. 12(4):17-25. X; X; 11:9.
  7. Wang T, PI Lerer I C, Peretz Z, C Sagi M C, Kaduri L C, Hubert A, C Abeliovich D. PI (1998) “A BRCA2 Mutation 8558delA in an Ashkenazi breast cancer patient.” Human Mutation; 12:291. 5.686; 19/157; 0.
  8. Hubert A PI, Peretz T C, Manor O C, Kaduri L C, Wienberg N C, Lerer I C, Sagi M C, Abeliovich D PI.(1998) “The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in prostate cancer Ashkenazi patients.” J. Human Genetics. 65(3):921-924. (Letter) 10.603; 8/157; 41:41.
  9. Hubert A, PI Lyass O, C Podeh D C, Gabizon A. PI (2000) “Doxil (Caelyx): an exploratory study with pharmokinetics in patients with hormone-refractory prostate cancer.” Anti Cancer Drugs, 11,123-127. 2.407; 107/194; 116/261; 52:50.
  10. Barak V PI, Nisman B C, Hubert A C, Lyass O, C Kaduri L, C Peretz T. PI (2000) “Prognostic efficiacy of TPS in breast cancer.” of Tumor Marker Oncology. 15(3):171-76 X; X; 2:2.
  11. Lotem M PI, Hubert A C, Lyass O C, Goldhersch MA C, Ingber A C, Peretz T C, Gabizon A. PI (2000) “Skin toxic effects of polyethylene glycol-coated liposomal Doxorubicin”. Arch Dermatol. 136(12):1475-80. 3.888; 4/58; 77:77.
  12. Kadouri L PI, Kote-Jarai Z C, Easton D.F C, Durocher F C, Hubert A C, Hamoudi R C, Abeliovich D C, Glaser B C, Peretz T C, Eeles R.A. PI (2001) “CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.” Br J Cancer. 6;85(1):36-40. 5.042; 32/194; 57:54.
  13. Lyass O PI, Hubert A PI, Gabizon A PI. (2001) “Phase I study of Doxi chemotherapy in patients with advanced amlignancies.” Clin Cancer Res. 7(10):3040-6. 742; 14/194; 24:24.
  14. Barak V PI, Nisman B C, Hubert A C, Lyass O C, Peretz T PI. (2002) “Cytokeratins-Clinical Utility in Breast Cancer” Clin.Lig.Assay. 25(1).40-42. X; X; 0.
  15. Shibolet O PI, Ilan Y C, Hubert A C, Shouval D C, Safadi R PI. (2002) “Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.” Blood. 15; 100(2): 391-6. 9.898; 2/68; 85:85.
  16. Rennert H PI, Bercovich D C, Hubert A C, Abeliovich D C, Rozovsky U C, Bar-Shira A C, Soloviov S C, Schreiber L C, Matzkin H C, Rennert G C, Kadouri L C, Peretz T C, Yaron Y C, Orr-Urtreger A PI. (2002) ”A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, Is Associated with Prostate Cancer in Ashkenazi Jews.” J Hum Genet.  71(4). 981-4. 10.603; 8/157; 79:79.
  17. Nisman B PI, Barak V C, Hubert A C, Kaduri L C, Lyass O C, Baras M C, Peretz T PI. (2003) “Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy”. Anticancer Res. 23(2C):1939-42. 1.725; 134/194; 8:8.
  18. Kaduri L PI, Kote-Jarai Z C, Easton D C, Hubert A C. Hamoudi R C, Glaser B C, Abeliovich D C, Peretz T C, Eeles RA PI. (2004) “Polyglutamine repeat length in the AIBI gene modifies breast cancer susceptibility in BRCA1 carriers” Int J Cancer. 20;108(3):399-403. 5.444; 26/194; 31:31.
  19. Kadouri L PI, Kote-Jarai Z C, Hubert A C, Durocher F C, Abeliovich D C, Glaser B C, Hamburger T T, Eeles RA C, Peretz T PI. (2004) “A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.” Br J Cancer. 17;90(10):2002-5. 5.042; 32/194; 63:63.
  20. Nissan A PI, Spira R C, Hamburger T T, Badriyyah M C, Prus D C, Cohen T C, Hubert A C, Fruend HR, Peretz T. (2004) “Clinical profile of breast cancer in Arab and jewish women in the Jerusalem area.” J.Surgery, 188:62-67. 2.776; 35/198; 11:11.
  21. Orr-Urtreger API, Bar-Shira AC, Bercovich D C, Matarasso N C, Rozovsky U C, Rosner S C, Soloviov S C, Rennert G C, Kadouri L C, Hubert A C, Rennert H C, Matzkin H PI (2006) “RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.” Cancer Epidemiol Biomarkers Prev. 15(3):474-9. 4.123; 44/194; 11/157; 16:16.
  22. Kadouri, L.PI, Hubert, A.PI, Rotenberg, Y.C, Hamburger, T.C, Sagi, M.C, Nechushtan, C.C, Abeliovich, D.C, Peretz, T.C (2007) “Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.” Med. Genet. 44: 467-471. 6.365; 17/157; 16:16.
  23. Goldberg Y, Porat R, Sagi M, Eilat A, Kedar I, Shochat C, Mendelson S, Hamburger T, Nissan A, Hubert A, Shalev S, Bercovich D, Pikarski E, Lerer I, Abeliovich D, Pretetz T. (2007) “A new oncogenetic service of counseling and diagnosing for hereditary non-polyposis colorectal cancer (HNPCC)”. Harefuah. Jul;146(7):510-4, 576, 575. Hebrew
  24. Yakir R, PI Luna K, C Marc W, C Tamar S, C Avraham R, C Ayala H. PI (2008) “The toxicity and outcomes of continuous 5-fluorouracil/based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute.” Ann Acad Med Singapore. 37(3):200-4.245; 68/153; 1:1
  25. Goldberg Y, PI Porat RM, C Kedar I, C Shochat C C, Sagi M, C Eilat A, C Mendelson S, C Hamburger T C, Nissan A, C Hubert A, C Kadouri L C, Pikarski E, C Lerer I, C Abeliovich D, C Bercovich D, C Peretz T. PI (2008) “Mutation spectrum in HNPCC in the Israeli population” Cancer 7(4):309-17. 1.302; 126/157; 152/194; 6:5.
  26. Barak V, Uziely B, Kaduri L, Nisman B, Hubert A, Kalickman I, Peretz T. “Prognosis Significance of Cytokeratins-TPS, TPA compared to Tumor mass Markers in Breast Cancer” Biomed Pharmacotherapy. 01/2009 63(5):328-328
  27. Goldzweig G, PI Hubert A, C Walach N, C Brenner B C Perry S, C Adritsch E, C Baider L. PI (2009) “Gender and psychological distress among middle and older aged colorectal cancer patients and their spouses: An unexpected outcome”. Crit Rev Oncol Hematol. 70(1):71-82. 4.411; 18/68; 37/194; 15:12.
  28. Kadouri L, PI Kote-Jarai Z, C Hubert A, C Baras M C, Abeliovich D C, Hamburger T, C Peretz T, Eeles R. PI (2009) “Glutathione S-Transferase M1, T1 and P1 Polymorphisms and Breast Cancer Risk in BRCA1/2 Mutation Carriers” Br J Cancer. 17;98(12):2006-10. 042; 32/194; 8:8.
  29. Goldzweig G, PI Andritsch E, C Hubert A, C Walach N, C Perry S, C Brenner B, C Baider L. PI (2009) “How Relevant is Marital Status and Gender Variables in Coping with Colorectal Cancer? A Sample of Middle-Aged and Older Cancer Survivors.” Psycho-oncology. 18)8:866-74. 3.339; 64/194; 15/75; 11:11.
  30. Hubert A, PI Mali B, C Hamburger T C, Rotternberg Y C, Uziely B C, Peretz T, C Kadouri L. PI (2009) “Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer” Cancer .8(3):173-7. 1.302; 126/157; 152/194; 9:9.
  31. Goldzweig G, PI Adritsch E C, Hubert A C, Brenner B, C Walach N, C Perry S, C Baider L. PI (2010) “Psychological distress amongst male patients and male spouses: What do oncologists need to know?” Oncol. 21(4):877-83. 6.425; 17/194; 1:1.
  32. Goldzweig G, PI Hason-Ohayon I C, Meirowitz A, C Braun M, C Hubert A, C Baider L. PI (2010) “Agents of Support: Psychometric Properties of the Cancer Perceived Agents of Social Support (CPASS) Questionnaire.” Psycho-oncology. 19(11):1179-86 3.339; 64/194; 15/75; 0.
  33. Goldzweig G, PI Meirowitz A C, Hubert A, C Brenner B, C Walach N, C Perry S, C Hason-Ohayon I C, Baider L. PI (2010) “Meeting expectations of patients with cancer: relationship between patient satisfaction, depression and coping.” J Clin Oncol. 20;28(9):1560-5. 372; 5/194; 4:4.
  34. Ospovat I, PI Siegelmann-Danieli N, C Grenader T, C Hubert A, C Hamburger T, C Peretz T. PI (2010) “Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients.” Tumori. 95(6):683-6. 606; 176/194; 2:2.
  35. Wygoda M, PI Rottenberg Y, PI Kadouri L, C Pikarsky A, C Hubert A. PI (2010) “Preoperative radiotherapy and concurrent chemotherapy with bolus 5-fluorouracil for rectal cancer: a prospective analysis of 98 patients” Tumori, 96: 709-712, 0.606; 176/194; 0.
  36. Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, Savion M, Pikarsky E, Abeliovich D, Bercovich D, Lerer I, Peretz T. (2010) “An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.” Fam Cancer. Jun;9(2):141-50.
  37. Sonnenblick A, PI Kadouri L C, Appelbaum L, C Peretz T, C Sagi M, C Goldberg Y C, Hubert A. PI (2011) “Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with based therapy.” Cancer Biol Ther. 1;12(3):165-8. 2.636; 90/194; 1:1.
  38. Hanna N, PI Ohana P C, Konikoff F, C Leichtmann G, C Hubert A, C Appelbaum L, C Aderka D, C Kopelman Y C, Czerniak A C, Hochberg A. PI (2012) “Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of BC-819 in Patients with Unresectable Pancreatic Cancer. “  Cancer Gene Therapy. 19(6)374-81. 2.802; 53/157; 69/157; 41/111; 84/194; 0.
  39. Sorin V. PI Ohana P C. Gallula J C. Birman T C, Matouk I. C Hubert A. C Gilon M. C Hochberg A C. Czerniak A. PI (2012) “H19-promoter targeted therapy combined with gemcitabine in the treatment of pancreatic cancer” .” ISRN Oncol. 2012;2012:351750. Epub 2012 Jun 3.
  40. Cohen I, PI Berant E C, Ayala H, C Perez T. PI (2012) “The mental health of breast cancer survivors and their adolescent daughters” Accepted: Psycho-Oncology. 3.339; 64/194; 15/75; 0.
  41. Sonnenblick A, PI Rottenberg Y C, Kadouri L, C Wygoda M, C Rivkind A C, Vaine GW, C Tamar Peretz C, Hubert A. PI (2012) “Long-term outcome of continuous 5-fluorouracil based chemotherapy followed by chemoradiation, in patients with resected  gastric cancer, and predictive value of ERCC1 and thymidylate synthase.”  Accepted Medical Oncology, 2.140; 115/194; 0.
  42. Salah A, PI Temper M C, Hamburger T C, Peretz T C, Hubert A. PI (2012) beyond first progression: continuation of combined and chemotherapy in second- line colon cancer therapy“. Accepted Tumori. 0.606; 176/194; 0.
  43. Golan T, PI Wolf E C, Shacham-Shmueli E C, Brener B C, Kundel Y C, Beny A C, Hubert A C, Idelevich E, C Klein B, C  Aderka D (2012) “Neoadjuvant therapy with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) and  in initially resectable colorectal liver metastases: correlation between morphologic, metabolic and pathologic responses.”  Submitted Am.J.Clin.Onc. 2.005; 121/194; 0.
  44. Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. ” Hypertension as a predictive biomarker in  treatment for colorectal cancer patients”. Med Oncol. 2013 Mar;30(1):327. doi: 10.1007/s12032-012-0327-4. Epub 2012 Dec 20.
  45. Grothey A, Van Cutsem E, et al. CORRECT Study Group. “Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial”. Lancet. 2013 Jan 26;381(9863):303-12.
  46. Breuer S, Maimon O, Appelbaum L, Peretz T, Hubert A. “TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.” Med Oncol. 2013 Jun;30(2):585. doi: 10.1007/s12032-013-0585-9. Epub 2013 Apr 23.
  47. Inbar C, Ety B, Ayala H, Tamer P. The mental health of breast cancer survivors and their adolescent daughters. Psychooncology. 2013 Jun;22(6):1236-41. doi: 10.1002/pon.3127. Epub 2012 Jul 4.
  48. Mahgerefteh S, Hubert A, Bloom AI “Clinical impact of percutaneous transhepatic insertion of metal biliary endoprostheses for palliation of jaundice and facilitation of chemotherapy.” American Journal of Clinical Oncology, 9/2013
  49. Goldberg Y, Kedar I, Kariiv R, Halpern N, Plesser M, Hubert A, Kaduri L, Sagi M, Lerer I, Abeliovich D, Hamburger T, Nissan A, Goldshmidt H, Solar I, Geva R, Strul H, Rosner G, Baris H, Levi Z, Peretz T. “Lynch Syndrome in high risk Ashkenazi Jews in Israel.” Fam Cancer. 2013 Aug 30.
  50. Elina Zorde Khvalevsky , Racheli Gabai , Itzhak-Haim Rachmut , Elad Horwitz , Zivia Brunschwig , Ariel Orbach , Shemi Adva , Talia Golan , Abraham J Domb , Eylon Yavin , Hilla Giladi , Ludmila Rivkin , Alina Simerzin , Rami Eliakim , Abed Khalaileh , Ayala Hubert , Maor Lahav , Yael Kopelman , Eran Goldin , Alan Dancour , Yael Hants , Sagit Arbel-Alon , Rinat Abramovitch , Amotz Shemi , Eithan Galun (corr-auth). “Mutant KRAS – a drugable target for pancreatic cancer” Proc Natl Acad Sci U S A. 2013 Dec 17;110(51). Epub 2013 Dec 2
  51. Tahover E, Hubert A, Temper M, Salah A, Peretz T, Hamburger T, Uziely B. “An Observational Cohort Study of  and Chemotherapy in Metastatic Colorectal Cancer Patients: Safety and Efficacy with Analysis by Age Group.” Target Oncol. 2014 Mar 6
  52. Goldberg Y, Kedar I, Kariiv R, Halpern N, Plesser M, Hubert A, Kaduri L, Sagi M, Lerer I, Abeliovich D, Hamburger T, Nissan A, Goldshmidt H, Solar I, Geva R, Strul H, Rosner G, Baris H, Levi Z, Peretz T “Lynch Syndrome in high risk Ashkenazi Jews in Israel.” Fam Cancer. 2014 Mar;13(1):65-73
  53. Matouk IJ, Raveh E, Abu-Lail R, Mezan S, Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M, Richler C, Fellig Y, Sorin V, Hubert A, Hochberg A, Czerniak A. Oncofetal “H19 RNA promotes tumor metastasis.” Biochim Biophys Acta. 2014 Jul;1843(7):1414-26.
  54. B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, M Friedlander, J Balmaña , G Mitchell, G Fried, S Stemmer, A Hubert, O Rosengarten10, M Steiner, N Loman, K Bowen, A Fielding and SM Domchek “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation”. J Clin Oncol. 2015 Jan 20;33(3):244-50
  55. Baruch Brenner, Ravit Geva, Megan Rothney, Alexander Beny, Ygael Dror, Mariana Steiner, Ayala Hubert, Efraim Idelevich, Alexander Gluzman, Ofer Purim, Einat Shacham-Shmueli, Katerina Shulman, Moshe Mishaeli, Sophia Mann, Lior Soussan-Gutman, Margarita Lopatin, Haluk Tezcan, Calvin Chao, Adi Shani, and Nicky Liebermann  “Impact of the 12-Gene Colon Cancer Assay on Clinical Decision-Making for Adjuvant Therapy in Stage II Colon Cancer Patients”  Submitted Plos One, 2014.
  56. Yael Goldberg, Inbal Barnes-Kedar, Israela Lerer, Naama Halpern, Morasha Plesser, Ayala Hubert, Luna Kaduri, Michal Sagi, Tamar Hamburger, Aviram Nissan, Hanoch Goldshmidt, Liat Ben Avi , Irit Solar, Hana Strul, Guy Rosner, Hagit N. Baris, Tamar Peretz,  Zohar Levi ,Revital Kariv “Genetic features of Lynch Syndrome in the Israeli population” Submitted: Clinical Genetic, 2014.
  57. Talia Golan, Elina Zorde, Khvalevsky, Ayala Hubert, Rachel Malka Gabai, Naama Hen, Amiel Segal, Abraham Domb, Gil Harari, Eli Ben David, Stephen Raskin, Yuri Goldes, Eran Goldin, Rami Eliakim,Maor Lahav, Yael Kopleman, Alain Dancour, Amotz Shemi, Eithan Galun “RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer: Results of a phase I trial” Oncotarget. 2015 May 19. [Epub ahead of print]
  58. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M. “Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.” Cancer Res. 2014 Sep 10. [Epub ahead of print]
  59. Tabernero J, Yoshino T, RAISE Study Investigators. et al. “Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.” Lancet Oncol. 2015 May;16(5):499-508. Epub 2015 Apr 12.
  60. Ron Epelbaum, Einat Shacham-Shmueli, Baruch Klein, Abed Agbarya, Baruch Brenner, Ronen Brenner, Eliahu Gez, Talia Golan, Ayala Hubert, Ofer Purim, Mark Temper, Ella Tepper, Andreas Voss, Kenneth Russell,  Addie Dvir,  Lior Soussan-Gutman, Salomon M. Stemmer,  and Ravit Geva. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study,” BioMed Research International, vol. 2015, Article ID 681653, 9 pages, 2015
  61. Jonathan E. Cohen, Yasmin Cohen, Tamar Peretz and Ayala Hubert “A Retrospective Study of the Predictive Value of “Target Now” in Systemic Therapy for Metastatic Colo-Rectal and Gastric Carcinomas”  Accepted for publiucation IMAJ 2015.
  62. Shachar Y, Adileh M, Keidar A, Eid L, Hubert A, Temper M, Azam S, Beny A, Grednader T, Khalaileh A, Yuval JB, Stojadinovic A, Avital I, Nissan A “Management of Inguinal Involvement of Peritoneal Surface Malignancies by Cytoreduction and HIPEC with Inguinal Perfusion.” J Cancer. 2015 Jan 18;6(3):243-6

Тематические отчеты:

  1. Leker R. Peretz T. Hubert A. Lossos A. (1997) “Vincristine – induced paralytic illeus in Parkinson’s disease.” Parkinsonism & Related Disorders. Vol.3, No.2: 109-110. 3.795; 35/191; 0.
  2. Lyass O, Lossos A, Hubert A, Gips M, Peretz T. (1998) induced nonconvulsive encephalopathy.” Anti-Cancer Drugs, Jan;9(1)100-4. 2.052;69/123;13. 2.407; 107/194; 116/261; 22:22.
  3. Lyass O, Gips M, Hubert A. (1998) “Small bowel metastases from lung cancer.” Harefua. V135: N10, Nov.15, (in Hebrew) X; X; 0.

 

departments: гастроэнтерология, онкология
positions: Руководитель центра диагностики и лечения опухолей ЖКТ
  •  Я принимаю условия
Вы можете прикрепить файлы! (в cумме до 100Мб)
еще файл

Пожалуйста, заполните поля и мы свяжемся с вами